Want to see IN:ZIMLAB full AI Analyst Report?
ZIMLAB Stock Chart & Stats
₹71.11
-₹1.76(-1.66%)
At close: 4:00 PM EST
₹71.11
-₹1.76(-1.66%)
Day’s Range― - ―
52-Week Range₹59.72 - ₹133.95
Previous CloseN/A
Volume52.11K
Average Volume (3M)6.28K
Market Cap
₹6.11B
Enterprise Value₹6.83B
Total Cash (Recent Filing)₹278.02M
Total Debt (Recent Filing)₹1.26B
Price to Earnings (P/E)94.9
Beta1.12
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.19
Shares Outstanding53,658,490
10 Day Avg. Volume5,950
30 Day Avg. Volume6,279
Financial Highlights & Ratios
PEG Ratio-0.97
Price to Book (P/B)1.00
Price to Sales (P/S)0.80
P/FCF Ratio-39.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Revenue Streams (branded + Contract Manufacturing)A dual revenue model —own branded/generic product sales plus contract development and manufacturing—provides durable demand channels. Contract manufacturing can yield multi-year supply contracts and stable volume, reducing single-channel dependence and supporting predictable manufacturing utilization over months.
Manufacturing Specialization In Oral Solid & Drug‑delivery FormulationsSpecialization in oral solid and drug‑delivery formulations creates technical capabilities and process know‑how that are harder to replicate. This supports differentiated product offerings, potential higher margins on formulation expertise, and sustained competitive positioning in core therapeutic and contract markets.
Balance Sheet Supported By Rising Equity And Moderate LeverageGrowing equity and moderate leverage provide a capital buffer and financing flexibility for capex or acquisitions. A stronger equity base lowers solvency risk, helping absorb temporary operating shocks and sustain investment in capacity or R&D across a multi‑month horizon.
Bears Say
Weakening Profitability And Margin PressureA sharp drop in net income and operating profit signals persistent margin pressure or adverse product mix. Lower profitability reduces retained earnings for reinvestment, weakens earnings quality, and can limit long‑term capacity to fund growth or cover rising costs without structural corrective actions.
Volatile Cash Conversion And Negative Free Cash FlowNegative and volatile free cash flow indicates working‑capital swings or elevated capex needs, constraining internal funding for expansion or debt reduction. Over several months this raises reliance on external financing and increases execution risk for product launches or contract fulfilment.
Rising Absolute Debt And Declining Returns On EquityIncreasing absolute debt raises fixed obligations and interest exposure, while falling ROE shows diminishing efficiency of capital deployment. Together these trends can weaken financial resilience and limit strategic flexibility if margins or cash flow do not recover sustainably.
Zim Laboratories Ltd. News
ZIMLAB FAQ
What was Zim Laboratories Ltd.’s price range in the past 12 months?
Zim Laboratories Ltd. lowest stock price was ₹59.72 and its highest was ₹133.95 in the past 12 months.
What is Zim Laboratories Ltd.’s market cap?
Zim Laboratories Ltd.’s market cap is ₹6.11B.
When is Zim Laboratories Ltd.’s upcoming earnings report date?
Zim Laboratories Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 4 days.
How were Zim Laboratories Ltd.’s earnings last quarter?
Zim Laboratories Ltd. released its earnings results on May 19, 2026. The company reported ₹0.76 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.76.
Is Zim Laboratories Ltd. overvalued?
According to Wall Street analysts Zim Laboratories Ltd.’s price is currently Overvalued.
Does Zim Laboratories Ltd. pay dividends?
Zim Laboratories Ltd. pays a Annually dividend of ₹0.167 which represents an annual dividend yield of N/A. See more information on Zim Laboratories Ltd. dividends here
What is Zim Laboratories Ltd.’s EPS estimate?
Zim Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zim Laboratories Ltd. have?
Zim Laboratories Ltd. has 53,658,490 shares outstanding.
What happened to Zim Laboratories Ltd.’s price movement after its last earnings report?
Zim Laboratories Ltd. reported an EPS of ₹0.76 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 5%.
Which hedge fund is a major shareholder of Zim Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:ZIMLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Zim Laboratories Ltd.
Established in 1984 and based in Nagpur, India, ZIM Laboratories Limited is a pharmaceutical company that develops, produces, and supplies both finished drug formulations and pre-formulation ingredients. Operating domestically and internationally, ZIM specializes in providing technology-driven drug delivery solutions and exclusive, non-infringing manufacturing processes for generic pharmaceuticals. These offerings span semi-finished and finished product categories, encompassing forms like granules, pellets, taste-masked powders, suspensions, tablets, capsules, and oral thin films. Their extensive product range caters to various therapeutic areas, including urology, gastroenterology, cardiology, and anticoagulation, alongside antibiotics, anti-infectives, NSAIDs/pain management, and vitamins and supplements.
Technical Analysis
Albert David Ltd
―
Bafna Pharmaceuticals Limited
―
Kilitch Drugs (India) Limited
―
Medico Remedies Ltd.
―
Valiant Laboratories Ltd.
―